Rhenman & Partners Asset Management AB — 13F Holdings & Portfolio
CIK 1599882 · latest 13F-HR filed 2026-08-13
Rhenman & Partners Asset Management AB manages $1.06B in 13F-reported U.S. long-equity assets across 99 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are UNH (3.67%), CVS (2.73%), AZN (2.69%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 21 new positions, exited 8, added to 49, and trimmed 21.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
STOCKHOLM 11451
$1.06B
Long-equity book
99
Distinct positions
2026-06-30
Filed 2026-08-13
+21 / −8 / ↑49 / ↓21
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- UNITED HEALTH GROUP INC$26.6M +216.0%
- DANAHER CORPORATION$11.9M +346.6%
- NURIX THERAPEUTICS INC$11.7M +241.6%
- EDWARDS LIFESCIENCES CORP$10.5M +80.2%
- BRIGHTSPRING HEALTH SVCS INC$9.4M +443.0%
Top Trims
- REGENERON PHARMACEUTICALS-$20.1M -54.0%
- BOSTON SCIENTIFIC CORP-$20.0M -51.0%
- VEEVA SYS INC-$11.9M -79.5%
- INSMED INC-$9.9M -38.0%
- MADRIGAL PHARMACEUTICALS INC-$8.3M -65.7%
New Positions
- ASTRAZENECA PLC$28.5M
- MERCK & CO INC$27.4M
- JOHNSON & JOHNSON$18.4M
- CENTENE CORP DEL$15.7M
- DEXCOM INC$10.8M
Exited Positions
- ADAPTIVE BIOTECHNOLOGIES COR$10.0M
- IQVIA HLDGS INC$9.0M
- NUVALENT INC$8.3M
- APOGEE THERAPEUTICS INC$6.3M
- ASCENDIS PHARMA A/S$3.4M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | UNITED HEALTH GROUP INC | UNH | 91324P102 | $38.9M | 3.67% | 93,600 | SH |
| 2 | CVS HEALTH CORP | CVS | 126650100 | $28.9M | 2.73% | 279,374 | SH |
| 3 | ASTRAZENECA PLC | AZN | G0593M107 | $28.5M | 2.69% | 151,500 | SH |
| 4 | MERCK & CO INC | MRK | 58933Y105 | $27.4M | 2.59% | 213,500 | SH |
| 5 | LILLY ELI & CO | LLY | 532457108 | $26.8M | 2.53% | 22,315 | SH |
| 6 | ABBVIE INC | ABBV | 00287Y109 | $24.4M | 2.30% | 96,775 | SH |
| 7 | ALIGNMENT HEALTHCARE INC | ALHC | 01625V104 | $23.7M | 2.24% | 997,083 | SH |
| 8 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $23.5M | 2.22% | 260,000 | SH |
| 9 | GILEAD SCIENCES INC | GILD | 375558103 | $22.5M | 2.13% | 178,250 | SH |
| 10 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $21.1M | 1.99% | 87,440 | SH |
| 11 | BIOGEN INC | BIIB | 09062X103 | $20.5M | 1.93% | 94,850 | SH |
| 12 | STRYKER CORPORATION | SYK | 863667101 | $20.5M | 1.93% | 65,000 | SH |
| 13 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $19.2M | 1.81% | 450,500 | SH |
| 14 | JOHNSON & JOHNSON | JNJ | 478160104 | $18.4M | 1.74% | 72,500 | SH |
| 15 | GUARDANT HEALTH INC | GH | 40131M109 | $17.3M | 1.63% | 115,000 | SH |
| 16 | REGENERON PHARMACEUTICALS | REGN | 75886F107 | $17.1M | 1.61% | 27,390 | SH |
| 17 | GLAUKOS CORP | GKOS | 377322102 | $16.6M | 1.57% | 119,000 | SH |
| 18 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $16.6M | 1.57% | 290,500 | SH |
| 19 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $16.6M | 1.57% | 684,250 | SH |
| 20 | NATERA INC | NTRA | 632307104 | $16.6M | 1.56% | 61,050 | SH |
| 21 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $16.3M | 1.54% | 139,205 | SH |
| 22 | INSMED INC | INSM | 457669307 | $16.2M | 1.53% | 151,960 | SH |
| 23 | TENET HEALTHCARE CORP | THC | 88033G407 | $15.9M | 1.50% | 85,200 | SH |
| 24 | THERMO FISHER SCIENTIFIC INC | TMO | 883556102 | $15.8M | 1.49% | 31,580 | SH |
| 25 | CENTENE CORP DEL | CNC | 15135B101 | $15.7M | 1.48% | 244,000 | SH |
| 26 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $15.4M | 1.46% | 63,050 | SH |
| 27 | DANAHER CORPORATION | DHR | 235851102 | $15.3M | 1.44% | 80,252 | SH |
| 28 | VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | $15.2M | 1.44% | 30,685 | SH |
| 29 | ANTERIS TECHNOLOGIES GLOBAL | AVR | 03675P102 | $15.2M | 1.43% | 1,538,625 | SH |
| 30 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $14.5M | 1.37% | 85,841 | SH |
| 31 | PENNANT GROUP INC | PNTG | 70805E109 | $13.7M | 1.30% | 371,471 | SH |
| 32 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $13.7M | 1.30% | 34,500 | SH |
| 33 | ELEVANCE HEALTH INC | ELV | 036752103 | $13.5M | 1.27% | 34,900 | SH |
| 34 | LIVANOVA PLC | LIVN | G5509L101 | $13.5M | 1.27% | 164,000 | SH |
| 35 | CENCORA INC | COR | 03073E105 | $13.2M | 1.25% | 46,778 | SH |
| 36 | CHARLES RIV LABS INTL INC | CRL | 159864107 | $13.0M | 1.22% | 57,200 | SH |
| 37 | IDEAYA Biosciences Inc | IDYA | 45166A102 | $12.8M | 1.21% | 343,800 | SH |
| 38 | MCKESSON CORP | MCK | 58155Q103 | $12.5M | 1.18% | 16,550 | SH |
| 39 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $12.2M | 1.16% | 560,250 | SH |
| 40 | BRIGHTSPRING HEALTH SVCS INC | BTSG | 10950A106 | $11.6M | 1.09% | 165,896 | SH |
| 41 | MEDTRONIC PLC | MDT | G5960L103 | $11.3M | 1.07% | 145,000 | SH |
| 42 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $11.2M | 1.06% | 416,371 | SH |
| 43 | OSCAR HEALTH INC | OSCR | 687793109 | $11.2M | 1.06% | 392,000 | SH |
| 44 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $11.0M | 1.04% | 197,000 | SH |
| 45 | DEXCOM INC | DXCM | 252131107 | $10.8M | 1.02% | 160,000 | SH |
| 46 | ALIGN TECHNOLOGY INC | ALGN | 016255101 | $10.6M | 1.00% | 63,000 | SH |
| 47 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $10.6M | 1.00% | 119,300 | SH |
| 48 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $10.6M | 1.00% | 566,000 | SH |
| 49 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 04280A100 | $10.4M | 0.98% | 128,000 | SH |
| 50 | AGILENT TECHNOLOGIES INC | A | 00846U101 | $10.0M | 0.94% | 75,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $1.06B | 99 | 0001213900-26-088652 |
| 2026-03-31 | 2026-05-14 | $810.5M | 86 | 0001213900-26-056196 |
| 2025-12-31 | 2026-02-13 | $1.07B | 94 | 0001213900-26-015821 |
| 2025-09-30 | 2025-11-13 | $903.7M | 92 | 0001213900-25-109534 |